<DOC>
	<DOCNO>NCT01709903</DOCNO>
	<brief_summary>To demonstrate non-inferiority QVA149 110/50 µg o.d . fluticasone/salmeterol 500/50 µg b.i.d . term trough Forced Expiratory Volume one second ( FEV1 ) ( mean 23 hour 15 min 23 hour 45 min post QVA149 dose ) follow 26 week treatment patient moderate severe COPD</brief_summary>
	<brief_title>A 26-week Treatment Randomized , Double-blind , Double Dummy Study Assess Efficacy Safety QVA149</brief_title>
	<detailed_description>To demonstrate non-inferiority QVA149 110/50 µg o.d . fluticasone/salmeterol 500/50 µg b.i.d . term trough Forced Expiratory Volume one second ( FEV1 ) ( mean 23 hour 15 min 23 hour 45 min post QVA149 dose ) follow 26 week treatment patient moderate severe COPD . The study population consist approximate 736 male female adult ( age 40 year great ) clinical diagnosis stable COPD [ GOLD ( 2010 ) ] smoke history least 10 pack year . It anticipate approximately 981 patient need screen order randomize 736 patient 2 treatment arm study equal randomization ratio , mean QVA149 ( 368 patient ) , fluticasone/salmeterol ( 368 patient ) . Treatment randomization stratify current/ex-smoker status prior ICS use . It intend 552 patient complete study Week 26 without major protocol deviation . Dropouts replace . This multi-national study , include China , least two country . Standardization FEV1 AUC0-12h perform subgroup around 100 patient ( 50 patient per treatment arm ) pre-selected center .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients moderate severe stable COPD ( Stage II Stage III ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guideline . Current exsmokers smoke history least 10 pack year . Patients postbronchodilator Forced Expiratory Volume one second ( FEV1 ) ≥ 30 % &lt; 80 % predict normal , postbronchodilator FEV1/FVC &lt; 0.7 . Modified Medical Research Council ( mMRC ) grade least 2 Visit 2 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive Human Chorionic Gonadotropin ( hCG ) laboratory test . Patents narrowangle glaucoma , symptomatic benign prostatic hyperplasia ( BPH ) , bladderneck obstruction , moderate severe renal impairment urinary retention . BPH patient stable treatment consider . Patients history long QT syndrome whose QTc measure runin ( Visit 2 ) ( Fridericia method ) prolong ( &gt; 450 m male female ) confirm central Electrocardiogram ( ECG ) assessor . Patients Type I uncontrolled Type II diabetes . Patients achieve spirometry result Visit 2 accordance American Thoracic Society/European Respiratory Society ( ATS/ERS ) criteria acceptability repeatability . Patients , ) history asthma , b ) onset respiratory symptom prior age 40 year . Patients concomitant pulmonary disease ( e.g . lung fibrosis , primary bronchiectasis , sarcoidosis , interstitial lung disorder , pulmonary hypertension ) . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
</DOC>